ALSO NOTED: FDA gives thumbs up to Hi-Tech Pharmacal drug;DC may license pharma reps;

> Hi-Tech Pharmacal got the FDA's OK to sell its version of Dermik Laboratories' Penlac nail fungus treatment. Release

> The District of Columbia's legislative body is considering a measure that would require all pharmaceuticals sales reps in the district to be licensed--and to get that license, they'd have to earn a bachelor's degree in pharmacy or science first. Report

> Aiming to boost its research into treatments for inflammatory diseases, German drug maker Evotec has agreed to buy U.S.-based Renovis for $151.8 million in stock. Report

> Merck has appointed ex-RJR Nabisco chief Steven Goldstone to its board. Release

> Meditrina Pharmaceuticals got the nod to manufacture the active ingredient in Pfizer CentreSource's drug candidate Femathina. Release

AND FINALLY... For two decades, biotech companies have struggled to develop therapeutic cancer vaccines. Now a crop of late-stage cancer vaccines are showing a lot of promise and attracting the attention of the large pharma and biotech companies. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.